Gross Profit Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.

Biotech Giants: Exelixis vs. MiMedx Gross Profit Showdown

__timestampExelixis, Inc.MiMedx Group, Inc.
Wednesday, January 1, 201423068000105558000
Thursday, January 1, 201533277000167094000
Friday, January 1, 2016184902000212608000
Sunday, January 1, 2017437411000285920000
Monday, January 1, 2018827478000322725000
Tuesday, January 1, 2019934678000256174000
Wednesday, January 1, 2020951266000208904000
Friday, January 1, 20211382097000215332000
Saturday, January 1, 20221553153000219525000
Sunday, January 1, 20231757661000266843000
Monday, January 1, 20242168701000
Loading chart...

Unleashing the power of data

Gross Profit Growth: Exelixis, Inc. vs. MiMedx Group, Inc.

In the dynamic world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Exelixis, Inc. and MiMedx Group, Inc. have shown contrasting trajectories in their gross profit margins. Exelixis, Inc. has experienced a remarkable growth, with its gross profit surging by over 7,500% from 2014 to 2023. This growth is a testament to its strategic advancements and market positioning. In contrast, MiMedx Group, Inc. has seen a more modest increase of approximately 150% during the same period, reflecting steady but slower progress.

The year 2023 marks a significant milestone, with Exelixis, Inc. achieving a gross profit nearly seven times that of MiMedx Group, Inc. This comparison highlights the varying growth strategies and market responses of these two companies, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025